NETCast

Podcasting4Associations
  • 0,0 (0)
  • Medicin

NETCast, brought to you by the North American Neuroendocrine Tumor Society (NANETS). Our episodes host leading neuroendocrine experts who will discuss the latest research, debate pros and cons of various treatment protocols, share information about establishing neuroendocrine centers, and much more.  Visit us at https://nanets.net/

  1. 27 maj

    Beyond the Data: How Physicians Talk to Patients About Uncertainty

    In this episode of NETCast, host Dr. Emil Lou is joined by a multidisciplinary panel of experts and a patient advocacy perspective to explore one of the most nuanced aspects of neuroendocrine tumor care: how physicians communicate uncertainty when the data are limited, evolving, or open to interpretation. Featuring perspectives from medical oncology, surgical oncology, nuclear medicine, and patient advocacy, the discussion examines the real-world challenges of navigating gray areas in NET care where multiple treatment paths may be reasonable and patient preferences play a critical role. The panel discusses how clinicians approach conversations when evidence is incomplete, communicate risk and treatment options, manage differing opinions within multidisciplinary teams, and build trust with patients facing complex decisions. Together, the group offers candid reflections and practical insights on balancing science, communication, and compassion in modern NET care. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  2. 6 apr.

    How Multidisciplinary Tumor Board Functions as the Engine Behind Complex NET Decision-Making

    In this live recording from the Nashville Regional, we will explore the real-world impact of multidisciplinary NET specialty centers, particularly for patients initially diagnosed or managed in community settings. What structurally changes when a patient transitions from community-based care to an academic institution? And further, what distinguishes a general academic center from a dedicated NET specialty center? This conversation will examine how multidisciplinary tumor board functions as the operational engine behind complex decision-making, the role of pathology reassessment, referral timing, access to specialized imaging and therapies, and how community and specialty centers can collaborate to optimize outcomes for patients with neuroendocrine tumors. The focus will be on systems of care and collaboration, rather than on a specific therapy or guideline update. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  3. 8 jan.

    Feocromocitoma y Paraganglioma (Spanish podcast on Pheochromocytoma & Paraganglioma)

    Este podcast médico presenta una discusión entre los Drs. Sarimar Agosto, Alejandro Román-González y Camilo Jiménez sobre el manejo del feocromocitoma y paraganglioma. Manejo multidisciplinario esencial (endocrinología, oncología, cirugía, genética, radiología nuclear). Referir pacientes a centros de excelencia. Cada caso requiere individualización del tratamiento según progresión, localización tumoral y estado global del paciente.  See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  4. 2025-12-22

    Hybrid Neuroendocrine Cancers: Pathology, Grade Transformation, and Emerging Therapies

    This NETCast episode features Dr. Uday Grewal hosting a discussion with Drs. Aman Chauhan, Renuka Iyer, and Shagufta Shaheen on the complexities of hybrid neuroendocrine cancers. The panel explores transformation cases, mixed histology, and emerging DLL3-targeted therapies with lung cancer and CAR-T expertise. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  5. 2025-12-15

    Hot Topics in NET Clinical Care

    This NETCast episode from the 2025 NANETS Symposium features Dr. Theodora Dimitra hosting a discussion with Drs. Alexandria Phan, Po H. Ear, Dawn Quelle, and Andrew Bellizzi on a range of hot topics. The panel discusses challenging NET clinical scenarios including biomarkers, GLP-1 medications, and surgical decision-making. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  6. 2025-12-08

    AI in Healthcare: Transforming NET Care Through Personalized Medicine

    This episode of NETCast features Dr. Thorvardur Halfdanarson (Mayo Clinic oncologist) and Burt Rosen (patient advocate) discussing artificial intelligence's role in transforming healthcare, particularly for NET patients. Both guests agree AI represents a truly transformative shift—not just another overhyped technology—with potential to revolutionize drug discovery, clinical trial design, and most importantly, move medicine from population-based treatment to individualized care. They also discuss key ethical considerations such as data ownership, patient consent for AI use in care, and ensuring models are trained on diverse populations to avoid amplifying existing biases. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  7. 2025-12-01

    Presidential Perspectives: The Evolution and Future of NET Care

    This episode of NETcast features a "presidential panel" of three distinguished NANETS leaders: Dr. Jennifer Chan (president 2025, Dana-Farber), Dr. Simran Singh (incoming president, Sunnybrook), and Dr. Thorvardur Halfdanarson (president emeritus, Mayo Clinic). The discussion covers transformative developments in NET management over the past decade, including radiopharmaceuticals, targeted therapies, and the recognition that NETs may be less rare than previously thought. The experts explore the future of alpha and beta particle therapy retreatment protocols, challenges in biomarker development, and the importance of treatment sequencing given disease heterogeneity. The panel also discusses the importance of mentorship and the welcoming nature of the NET community in nurturing early-career researchers, while acknowledging that future progress will likely come through incremental advances and optimal treatment sequencing rather than single breakthrough therapies. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

  8. 2025-11-24

    NET Patient Advocacy: A Multi-Stakeholder Perspective

    This episode of NETCast features a panel on NET patient advocacy. They explore why advocacy is critical for this rare cancer, discussing challenges patients face at diagnosis, the importance of education and resources, research funding obstacles, and political advocacy efforts. The panel emphasizes that patients should be active participants in advocacy—whether through contacting reprsentatives, supporting research organizations, or engaging in educational initiatives—to make this "invisible" disease visible and drive meaningful change in treatment and outcomes. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Visa alla (45)

Trailer

Om

NETCast, brought to you by the North American Neuroendocrine Tumor Society (NANETS). Our episodes host leading neuroendocrine experts who will discuss the latest research, debate pros and cons of various treatment protocols, share information about establishing neuroendocrine centers, and much more.  Visit us at https://nanets.net/

Information

  • Skapad av
    Podcasting4Associations
  • Aktiva år
    2022 - 2026
  • Avsnitt
    45
  • Åldersgräns
    Barnvänligt
  • Copyright
    © 2022
  • Programmets webbplats
    NETCast